Business Overview: Aura Biosciences, Inc. (NASDAQ: AURA)

---

Executive Summary

Aura Biosciences, Inc., headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company developing a novel class of cancer therapeutics based on a proprietary virus-like particle (VLP) technology platform. Aura's lead product candidate, bel-sar (belzupacap sarotalocan), is being developed as a light-activated, targeted therapy for choroidal melanoma, a rare eye cancer, with the goal of destroying tumor cells while preserving vision — a significant potential improvement over current standard-of-care treatments (such as plaque radiotherapy or enucleation/eye removal) that often result in significant vision loss. As a clinical-stage company, Aura generates no meaningful product revenue today.

---

1. Core Business Model & How They Work

Aura's business model centers on advancing its VLP-based targeted conjugate platform through clinical trials toward FDA approval, initially in ocular oncology, with potential expansion into other cancers where the platform's tumor-targeting and light-activation mechanism could apply.

[ VLP Platform Engineering (Tumor-Targeting + Light-Activated Payload) ] ➡️ [ Clinical Development in Choroidal Melanoma (bel-sar) ] ➡️ [ Pivotal Phase 3 Trial ] ➡️ [ FDA Approval ] ➡️ [ Commercialization via Ophthalmic Oncology Specialists / Partnership ] ➡️ [ Platform Expansion to Additional Ocular & Other Tumors ]

Key Operational Drivers

1. Vision-Preserving Mechanism: Bel-sar is designed to selectively bind tumor cells and, upon activation by a specific light wavelength delivered via ophthalmic laser, destroy cancerous cells while sparing surrounding healthy retinal and ocular tissue — directly addressing the major drawback (vision loss) of current choroidal melanoma treatments.
2. Orphan/Rare Disease Positioning: Choroidal melanoma is a rare cancer, giving Aura a potential path to orphan drug designation benefits (market exclusivity, regulatory incentives) and a specialized, manageable target prescriber base of ocular oncologists.
3. Platform Extensibility: Aura's VLP conjugate technology is designed to be a platform, with potential to extend to other ocular tumors (such as ocular surface squamous neoplasia) and, longer term, other cancer types beyond ophthalmology.
4. Capital Markets Dependent Funding: As a clinical-stage biotech, Aura funds its pivotal trials and operations primarily through equity capital markets.

---

2. Competitive Landscape

                  Vision-Destructive Standard of Care
                              │
              Plaque radiotherapy, enucleation (eye removal),
              proton beam therapy — established but vision-
              compromising treatments  ●
                              │
   ───────────────────────────┼───────────────────────────
     Vision-Preserving, Targeted Approach
                              │
                    Aura Biosciences ●
                 (bel-sar — light-activated,
                  tumor-targeted VLP conjugate)

Competitors

• Established radiotherapy and surgical approaches (plaque brachytherapy, proton beam therapy, enucleation): The current standard of care for choroidal melanoma that bel-sar aims to improve upon, primarily by preserving vision and reducing treatment-related complications.
• Other ocular oncology and rare eye disease drug developers: A smaller field of biotech companies pursuing novel treatments for rare ophthalmic cancers and conditions, representing potential future competitive or platform-adjacent overlap.
• Academic ocular oncology treatment centers: Represent the specialized referral centers where choroidal melanoma patients are typically treated today and where bel-sar, if approved, would need to gain clinical adoption.

---

3. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• A genuinely novel, patent-protected VLP-based targeted conjugate technology platform with a differentiated vision-preserving mechanism of action.
• Orphan disease positioning in choroidal melanoma provides a focused, achievable initial commercial target with potential regulatory exclusivity benefits.
• Platform extensibility to additional ocular and potentially non-ocular tumors provides pipeline optionality beyond the lead indication.

Strategic Risks & Vulnerabilities

1. Binary clinical and regulatory risk: As with all clinical-stage biotechs, Aura's value depends heavily on pivotal trial outcomes and FDA approval, which are inherently uncertain. Mitigation: earlier-phase clinical data supporting the pivotal trial design.
2. Small initial addressable market: Choroidal melanoma is a rare disease, limiting the near-term revenue opportunity from bel-sar alone. Mitigation: platform expansion into additional ocular and other tumor indications increases the long-term addressable market.
3. Capital markets dependency and dilution risk: Continued equity financing to fund pivotal trials and potential launch preparation dilutes existing shareholders. Mitigation: potential partnership or licensing arrangements as pivotal data matures.
4. No existing commercial infrastructure: Aura would need to build or partner for commercialization targeting the specialized ocular oncology community if bel-sar is approved. Mitigation: the concentrated, specialized nature of ocular oncology treatment centers makes a focused commercial launch more achievable than a mass-market product.

---

4. Financial Overview

---

5. Summary Conclusion

Aura Biosciences has developed a scientifically differentiated, vision-preserving approach to treating choroidal melanoma using its proprietary virus-like particle conjugate platform, directly addressing the major drawback of current radiotherapy- and surgery-based standards of care that often result in significant vision loss.

The central strategic question is pivotal trial execution and platform expansion: Aura's near-term value depends on generating compelling pivotal data for bel-sar in choroidal melanoma and securing FDA approval, after which the company must decide how to commercialize within the specialized ocular oncology community while continuing to invest in extending its VLP platform to additional ocular and potentially broader oncology indications.